ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
What Biotech and Pharma need to consider about decentralised trials
Emily Mitchell, Executive Director, DCT Operations discusses the key considerations when implementing decentralised clinical trials, in addition to the success factors that lead to more patient-centric trials and increased patient recruitment, engagement and retention.
The surge of digital health technologies modernising clinical research
Dr. Isaac R. Rodriguez-Chavez outlines the key considerations when developing digital health technologies.
Cell and gene therapy specific market authorisation guidances
Brandon Fletcher, Principal, Cell and Gene Therapy, offers his insights on the key changes in regulatory guidance documents released by the US Food and Drug Agency.
Improving early phase oncology clinical trial design using Bayesian-based BOIN and BOP2 designs
Tim Clark, VP Drug Development Solutions, Martin Lachs, VP Project Management Oncology & Cell Therapeutics and Alan Phillips, Sr. Director Biostatistics, offer insights on selecting and implementing the appropriate model-based or model-assisted design for early phase oncology trials.
Evaluating similarities and differences between machine learning and traditional statistical modeling in healthcare analytics
ICON experts explain why data scientists and analysts should not necessarily have to choose between either machine learning or statistical modeling as a mutually exclusive decision tree.
The innovative 'digiverse' that's propelling transformative decentralised clinical trials
Dr. Isaac R. Rodriguez-Chavez offers his insights on the use of innovative digital health technologies and digital ecosystems to support decentralised clinical trials.
Steve Cutler features in Executive Insights in association with KPMG
This article features an interview with Steve Cutler after ICON won Company of the Year.
ICON reveals record €2.28bn business win in Q1
Steve Cutler is quoted in this article on the record earnings ICON achieved in the first quarter of 2022 despite the ongoing disruption from the war in Ukraine.
Precision medicine
Ewa Kleczyk, Vice President, Advanced & Custom Analytics, offers her insights on the use of precision medicine in clinical trials.
How can real world data improve clinical trial outcomes?
Kathleen Mandziuk, VP of Project Management and Real-World Solutions, offers her insights on the use of real world data to improve clinical trials outcomes.